Table 3.
Description of the best immune subpopulations biomarkers in the overall survival setting.
| NSCLC Immunotherapy Treatment Group | Non-Immunotherapy Treatment Control Group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarkers | N | Median | Range | Percentile 55 (n Patients, %) | Percentile 45 (n Patients, %) | N | Median | Range | Percentile 55 (n Patients, %) | Percentile 45 (n Patients, %) |
| CD3+CD4+ | 36 | 25.06 | 1.3–60.4 | N = 16 23.5% |
N = 16 18.8% |
37 | 27.22 | 3.5–64.6 | N = 17 26.4% |
N = 17 20.0% |
| CD3+CD4+CCR9+ | 36 | 5.10 | 0.4–57.6 | N = 16 1.7% |
N = 17 1.3% |
37 | 5.06 | 0.4–70.4 | N = 17 1.6% |
N = 17 1.4% |
| CD3+CD4+CCR10+ | 36 | 5.59 | 0.4–59.3 | N = 16 2.8% |
N = 16 2.2% |
37 | 7.15 | 0.4–83.1 | N = 17 3.7% |
N = 17 2.4% |
| CD3+CD8+CXCR4+ | 36 | 50.95 | 27–98.1 | N = 16 73.7% |
N = 16 72.2% |
37 | 48.97 | 27.0–98.1 | N = 17 75.9% |
N = 17 73.6% |
| CD11c+CD14-MHCII+CD123+ | 36 | 71.36 | 22.9–95.5 | N = 16 79.8% |
N = 16 75.8% |
37 | 61.67 | 22.9–95.5 | N = 17 70.7% |
N = 18 68.1% |
| CD56+CCR9+ | 36 | 3.19 | 0.2–50.5 | N = 16 1.4% |
N = 16 1.2% |
37 | 4.00 | 0.2–50.5 | N = 17 1.5% |
N = 17 1.3% |